Skip to main content
English
Català
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
6 December 2016
ORYZON Announces Encouraging Top-line Results from Phase I-IIA Clinical Trial in Acute Leukemia of RG6016 (ORY-1001) at the American Society of Hematology 2016 Annual Meeting
14 November 2016
ORYZON to Present Clinical Data on LSD1 Inhibitor ORY-1001 at ASH 2016
7 November 2016
ORYZON Announces Exercise of Warrants by Alzheimer’s Drug Discovery Foundation (ADDF)
26 October 2016
ORYZON Genomics to Present at Stifel 2016 Healthcare Conference
24 October 2016
ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016
29 September 2016
ORYZON AT BIOSPAIN 2016
26 September 2016
ORYZON Closes € 5.3 Million (6 M USD) in additional Debt Financing
14 September 2016
ORYZON Selected as one of the Finalist for the 7th Annual Most Innovative EU Biotech SME Award
12 September 2016
Oryzon to Present ORY-2001 Preclinical efficacy data in Multiple Sclerosis animal model at ECTRIMS-2016 Annual Meeting
1 September 2016
Oryzon Genomics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and at BioPharm America 2016
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »